BioSpace News Archive

There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.

IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.

ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.

In its announcement today, OncoSec said the deal is pivotal to the company’s future. It claimed that South Korea-based Alpha Holdings, which has about 15% of the company’s stock, has been making “false and misleading statements” as it urges shareholders to oppose the deal.

Under the terms of the deal with BBA, BBA acquired a capped 4.5% royalty on net sales of KSI-301 that will be paid upon marketing approval.

Be ready by anticipating and countering objections the employer might raise.

Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.

Oncopeptides AB announced that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc. Joseph will serve on the Management Team of Oncopeptides.

Eli Lilly and Company’s (NYSE: LLY) first digital health open innovation challenge, “Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease,” has concluded, with HealthVoyager, an application developed by Boston Children’s Hospital and Klick Health, being named the winner.

Oramed’s Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.